Introduction
For treatment of atherosclerotic patients at high risk of cardiac failure, stents have been in clinical use routinely for many years now. However, re-endothelialisation of secondgeneration cardiovascular implants is still a major concern [1] . The formation of an intact endothelium at the vesselstent interface straight after implantation is of key importance for preventing thrombosis as well as restenosis. Therefore we attempted to improve endothelialisation of poly(ε-caprolactone), a polymer often used in artificial vessel development [2, 3] , via three different strategies: 1. chemical surface activation, 2. precoating with proteins of the extracellular matrix, and 3. stimulation of endothelial growth with specific growth factor. In order to provide insights into the materials' feasibility for use in cardiovascular stents, we are using primary human umbilical vein endothelial cells (HUVECs) in vitro to test surface-functionalized polymers for both their biocompatibility and cell stimulatory potential.
Methods
The surface of poly(ε-caprolactone) (PCL) was activated with functional groups either through wet chemical processes or through oxygen or nitrogen plasma, and the resulting modifications were verified by contact angle measurement, X-ray photoelectron spectroscopy (XPS) and infrared spectroscopy, as well as examined by means of electron microscopy ( Fig. 1 ). Activated polymers were tested for their biocompatibility. Alternatively, untreated PCL was coated with either fibronectin, laminin or collagen I. The effect of cross-linking these matrix proteins immediately prior to their use for coating of PCL was also investigated. Using primary cell culture, human umbilical cord endothelial cells (HUVECs) were grown on the various polymer surfaces and appropriate controls and subjected to both viability and proliferation assays. These assays were also used to validate the stimulation of endothelial cells with vascular endothelial growth factor (VEGF). In addition, endothelial cell adhesion to PCL was monitored through confocal laser scanning microscopy.
Results
Surface modification of PCL did not result in significant changes to the polymer's morphology (Fig. 1) , but led to an overall decrease in contact angle and a corresponding increase in hydrophilicity of the originally hydrophobic material. Accordingly, cell viability on modified surfaces was higher than on untreated PCL, particularly in the presence of VEGF, as depicted in Fig. 2 . We were able to achieve consistently improved adhesion of human endothelial cells by precoating the PCL polymer with either of three extracellular matrix proteins. However, crosslinking of the proteins prior to the coating procedure did not promote endothelial cell adhesion (Fig. 3 ). The results obtained through biocompatibility testing were complemented with confocal laser scanning microscopy, where the positive influence of VEGF growth factor on HUVECs adhesion to PCL was particularly noticeable.
Discussion
While differences in endothelial cell viability are minor when differently activated PCL surfaces are compared, the highest values are seen with plasma activation and matrix protein precoating, respectively. These results are in accordance with previously published findings on HUVECs-matrix adhesion on degradable polymer scaffolds [4] . Crosslinking of extracellular matrix protein right before their implementation as a coating on the polymer surface seemingly does not convey any beneficial effects on the adhesion of human endothelial cells in vitro. The combination of plasma treatment and protein coating of PCL has already yielded encouraging results for cell colonization of implant material [5] . When different strategies are combined, the VEGF stimulation of HUVECs on PCL activated with plasma appears to hold the most potential for reendothelialisation. We are confident that the strategies described here will contribute to better endothelialisation of stent surfaces and hence reduce post-implantation complications.
